The reasons and timing of the oral transmucosal fentanyl administration in Japan

Abstract only e21665 Background: The oral transmucosal fentanyl disintegrating tablet, Abstral, is a formulation by which fentanyl can be rapidly absorbed across the oral mucosa producing rapid onset analgesia, and which may be effective for breakthrough cancer pain. It can be administered for the p...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical oncology Vol. 35; no. 15_suppl; p. e21665
Main Authors:	Kajiura, Shinya, Kashii, Tatsuhiko, Takaki, Akiyoshi, Chikaoka, Shingo, Hayashi, Naomi, Matsushita, Takako, Kadota, Ayaka, Fukai, Sakie, Nakaya, Rumi, Tachida, Natsumi, Yamamoto, Keiko, Nakajima, Kazunori, Horikawa, Hideyo, Takemura, Yoshinori, Shima, Tomoko, Furuichi, Astushi, Ando, Takayuki, Miwa, Toshiro, Murakami, Nozomu
Format:	Journal Article
Language:	English
Published:	20-05-2017
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract only e21665 Background: The oral transmucosal fentanyl disintegrating tablet, Abstral, is a formulation by which fentanyl can be rapidly absorbed across the oral mucosa producing rapid onset analgesia, and which may be effective for breakthrough cancer pain. It can be administered for the patients who cannot take the oral medicine. It has been marketed since 2014 in Japan. Methods: We selected patients who were administered Abstral for breakthrough cancer pain between 2014 and 2016 at Toyama University Hospital in Japan. We retrospectively investigated administration reasons based on medical record of those patients. Results: There were 111 patients who were administered Abstral. Primary lesions of lung/Gastrointestin/others were 43/52/16, respectively. ECOG PS 0-2/3-4 were 27/84, respectively. The median age was 66 y.o. (range 35-91 y.o.). Regularly using opioid were fentanyl patch prescribed for all patients. Median dose of fentanyl patch was 25mcg/hr (range 12.5-250mcg/hr). 90 patients (81%) had difficulties in the administration of oral medicine, which was the main reason of Abstral administration. Four patients (4%) were to reduce constipation and vomiting as side effects of oxycodone. Seven patients (6%) were to start a fentanyl patch. Three patients (3%) were assessed poor effect for short-acting opioid. Only seven patients (6%) were expected of rapid onset of analgesia effect. Abstral was administered in 27 patients (24%) during aggressive treatment such as chemotherapy administration and in 84 patients (76%) after aggressive treatment. Conclusions: The oral transmucosal fentanyl was administered for the patients who cannot take the oral medicine in Japan while it is expected to be administered to those who want to relieve breakthrough pain fast. Affirming a common understanding of the efficacy of the oral transmucosal fentanyl and breakthrough cancer pain is necessary in Japan.
ISSN:	0732-183X 1527-7755
DOI:	10.1200/JCO.2017.35.15_suppl.e21665